MDM2 and Prognosis

Molecular Cancer Research

Volumn 2, Issue 1, 2004, Pages 1-8

  Onel, Kenan ^a   Cordon Cardo, Carlos ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

AUTOREGULATION; CANCER RECURRENCE; CANCER THERAPY; CARCINOGENESIS; CARCINOMA; FEEDBACK SYSTEM; GENE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENOME; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; MALIGNANT TRANSFORMATION; MDM2 GENE; MELANOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION; PROTO ONCOGENE; REVIEW; SARCOMA; STRESS; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0842304206     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Vogelstein, B., Lane, D., and Levine, A. J. Surfing the p53 network. Nature, 408: 307-310, 2000.
2. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
3. Piette, J., Neel, H., and Marechal. V. Mdm2: keeping p53 under control. Oncogene, 15. 1001-1010, 1997.
4. Jones, S. N., Hancock, A. R., Vogel, H., Donehower, L. A., and Bradley, A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA, 95: 15608-15612, 1998.
5. Momand, J., Jung, D., Wilczynski, S., and Niland, J. The MDM2 gene amplification database. Nucleic Acids Res., 26: 3453-3459, 1998.
6. Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky. D., Kinzler, K. W., and Vogelstein, B. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res., 53: 2231-2234, 1993.
7. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F., and Levine, A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54: 794-799, 1994.
8. Wurl, P., Meye, A., Berger, D., Bache. M., Lautenschlager, C., Schmidt, H., Kalthoff, H., Rath, F. W., and Taubert, H. Prognostic relevance of C-terminal Mdm2 detection is enhanced by p53 positivity in soft tissue sarcomas. Diagn. Mol. Pathol., 6: 249-254, 1997.
9. Wurl, P., Meye, A., Schmidt, H., Lautenschlager, C., Kalthoff, H., Rath, F. W., and Taubert, H. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene, 16: 1183-1185, 1998.
10. Wurl, P., Meye, A., Berger, D., Lautenschlager, C., Bache, M., Holzhausen, H. J., Schmidt, H., Dralle, H., Rath, F. W., and Taubert, H. Significance of retinoblastoma and mdm2 gene expression as prognostic markers for soft-tissue sarcoma. Langenbecks Arch. Surg., 383: 99-103, 1998.
11. Bartel, F., Meye, A., Wurl, P., Kappler, M., Bache, M., Lautenschlager, C., Grunbaum, U., Schmidt, H., and Taubert, H. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma. Int. J. Cancer, 95: 168-175, 2001.
12. Tsuchiya, T., Sekine, K., Hinohara, S., Namiki, T., Nobori, T., and Kaneko, Y. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet. Cytogenet., 120: 91-98, 2000.
13. Waber, P. G., Chen, J., and Nisen, P. D. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res., 53: 6028-6030, 1993.
14. Taylor, A. C., Shu, L., Danks, M. K., Poquette, C. A., Shetty, S., Thayer, M. J., Houghton, P. J., and Harris, L. C. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med. Pediatr. Oncol., 35: 96-103, 2000.
15. Antonescu, C. R., Leung, D. H., Dudas, M., Ladanyi, M., Brennan, M., Woodruff, J. M., and Cordon-Cardo, C. Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications. Am. J. Pathol., 156: 977-983, 2000.
16. Oda, Y., Sakamoto, A., Satio, T., Kawauchi, S., Iwamoto, Y., and Tsuneyoshi, M. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Mod. Pathol., 13: 994-1004, 2000.
17. Schiebe, M., Ohneseit, P., Hoffmann, W., Meyermann, R., Rodemann, H. P., and Bamberg, M. Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J. Neurooncol., 49: 197-203, 2000.
18. Reifenberger, G., Reifenberger, J., Ichimura, K., and Collins, V. P. Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site. Cancer Res., 55: 731-734, 1995.
19. Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E. E., and Collins, V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res., 53: 2736-2739, 1993.
20. Korkolopoulou, P., Christodoulou, P., Kouzelis, K., Hadjiyannakis, M., Priftis, A., Stamoulis, G., Seretis, A., and Thomas-Tsagli, E. MDM2 and p53 expression in gliomas: a mulivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br. J. Cancer, 75: 1269-1278, 1997.
21. Rainov, N. G., Dobberstein, K. U., Bahn, H., Holzhausen, H. J., Lautenschlager, C., Heidecke, V., and Burkert, W. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppresor gene products on survival. J. Neurooncol., 35: 13-28, 1997.
22. Olson, J. J., Barnett, D., Yang, J., Assietti, R., Cotsonis, G., and James, C. D. Gene amplification as a prognostic factor in primary brain tumors. Clin. Cancer Res., 4: 215-222, 1998.
23. Korshunov, A., Golanov, A., and Sycheva, R. Immunohistochemical markers for prognosis of cerebral glioblastomas. J. Neurooncol., 58: 217-236, 2002.
24. Galanis, E., Buckner, J., Kimmel, D., Jenkins, R., Alderete, B., O'Fallon, J., Wang, C. H., Scheithauer, B. W., and James, C. D. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int. J. Oncol., 13: 717-724, 1998.
25. Bueso-Ramos, C. E., Yang, Y., de Leon, E., McCown, P., Stass, S. A., and Albitar, M. The human MDM-2 oncogene is overexpressed in leukemias. Blood, 82: 2617-2623, 1993.
26. Quesnel, B., Preudhomme, C., Oscier, D., Lepelley, P., Collyn-d'Hooghe, M., Facon, T., Zandecki, M., and Fenaux, P. Overexpression of the MDM2 gene is found in some cases of haematological malignancies. Br J. Haematol., 88: 415-418, 1994.
27. Marks, D. I., Kurz, B. W., Link, M. P., Ng, E., Shuster, J. J., Lauer, S. J., Brodsky, I., and Haines, D. S. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood, 87: 1155-1161, 1996.
28. Marks, D. I., Kurz, B. W., Link, M. P., Ng, E., Shuster, J. J., Lauer, S. J., Carroll, D., Brodsky, I., and Haines, D. S. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J. Clin. Oncol., 15: 1158-1162, 1997.
29. Zhou, M., Gu, L., Abshire, T. C., Homans, A., Billett, A. L., Yeager, A. M., and Findley, H. W. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia, 14: 61-67, 2000.
30. Gustafsson, B. and Stal, O. Overexpression of MDM2 in acute childhood lymphoblastic leukemia. Pediatr. Hematol. Oncol., 15: 519-526, 1998.
31. Gustafsson, B., Axelsson, B., Christensson, B., and Winiarski, J. MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors. Pediatr. Hematol. Oncol., 18: 497-508, 2001.
32. Moller, M. B., Nielsen, O., and Pedersen, N. T. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod. Pathol., 12: 1010-1016, 1999.
33. Pagnano, K. B., Vassallo, J., Lorand-Metze, I., Costa, F. F., and Saad, S. T. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggresive non-Hodgkin's lymphomas. Am. J. Hematol., 67: 84-92, 2001.
34. Moller, M. B., Nielsen, O., and Pedersen, N. T. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. Histopathology, 41: 322-330, 2002.
35. Finnegan, M. C., Goepel, J. R., Royds, J., Hancock, B. W., and Goyns, M. H. Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin's lymphomas. Cancer Lett., 86: 215-221, 1994.
36. Polsky, D., Bastian, B. C., Hazan, C., Melzer, K., Pack, J., Houghton, A., Busam, K., Cordon-Cardo, C., and Osman, I. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res., 61: 7642-7646, 2001.
37. Polsky, D., Melzer, K., Hazan, C., Panageas, K. S., Busam, K., Drobnjak, M., Kamino, H., Spira, J. G., Kopf, A. W., Houghton, A., Cordon-Cardo, C., and Osman, I. HDM2 protein overexpression and prognosis in primary malignant melanoma. J. Natl. Cancer Inst., 94: 1803-1806, 2002.
38. Higashiyama, M., Doi, O., Kodama, K., Yokouchi, H., Kasugai, T., Ishiguro, S., Takami, K., Nakayama, T., and Nishisho, I. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is favourable prognostic marker in patients without p53 protein accumulation. Br. J. Cancer, 75: 1302-1308, 1997.
39. Ko, J. L., Cheng, Y. W., Chang, S. L., Su, J. M., Chen, C. Y., and Lee, H. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer. Int. J. Cancer, 89: 265-270, 2000.
40. Bueso-Ramos, C. E., Manshouri, T., Haidar, M. A., Yang, Y., McCown, P., Ordonez, N., Glassman, A., Sneige, N., and Albitar, M. Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res. Treat., 37: 179-188, 1996.
41. Lukas, J., Gao, D. Q., Keshmeshian, M., Wen, W. H., Tsao-Wei, D., Rosenberg, S., and Press, M. F. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res., 61: 3212-3219, 2001.
42. Hori, M., Shimazaki, J., Inagawa, S., and Itabashi, M. Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res. Treat., 71: 77-83, 2002.
43. Phelps, M., Darley, M., Primrose, J. N., and Blaydes, J. P. p53-independent activation of the hDM2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res., 63: 2616-2623, 2003.
44. Kartasheva, N. N., Contente, A., Lenz-Stoppler, C., Roth, J., and Dobbelstein, M. p53 induces the expression of its antagonist p73 Δ N, establishing an autoregulatory feedback loop. Oncogene, 21: 4715-4727, 2002.
45. Nakagawa, T., Takahashi, M., Ozaki, T., Watanabe Ki, K., Todo, S., Mizuguchi, H., Hayakawa, T., and Nakagawara, A. Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol. Cell. Biol., 22: 2575-2585, 2002.
46. Alarcon-Vargas, D., Fuchs, S. Y., Deb, S., and Ronai, Z. p73 transcriptional activity increases upon cooperation between its spliced forms. Oncogene, 19, 831-835, 2000.
47. Ghioni, P., Bolognese, F., Duijf, P. H., Van Bokhoven, H., Mantovani, R., and Guerrini, L. Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol. Cell. Biol., 22: 8659-8668, 2002.
48. Dohn, M., Zhang, S., and Chen, X. p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene, 20: 3193-3205, 2001.
49. Calabro, V., Mansueto, G., Parisi, T., Vivo, M., Calogero, R. A., and La Mantia, G. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J. Biol. Chem., 277: 2674-2681, 2002.
50. Little, N. A. and Jochemsen, A. G. Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. Oncogene, 20: 4576-4580, 2001.
51. Wang, X. Q., Ongkeko, W. M., Lau, A. W., Leung, K. M., and Poon, R. Y. A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res., 61: 1598-1603, 2001.
52. Park, B. J., Lee, S. J., Kim, J. I., Lee, C. H., Chang, S. G., Park, J. H., and Chi, S. G. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res., 60: 3370-3374, 2000.
53. Crook, T., Nicholls, J. M., Brooks, L., O'Nions, J., and Allday, M. J. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene, 19: 3439-3444, 2000.
54. Naka, M., Ozaki, T., Takada, N., Takahashi, M., Shishikura, T., Sakiyama, S., Tada, M., Todo, S., and Nakagawara, A. Functional characterization of naturally occurring mutants (P405R and P425L) of p73alpha and p73beta found in neuroblastoma and lung cancer. Oncogene, 20: 3568-3572, 2001.
55. Zhang, H. and Rosdahl, I. Expression of oncogenes, tumour suppressor, mismatch repair and apoptosis-related genes in primary and metastatic melanoma cells. Int. J. Oncol., 19: 1149-1153, 2001.
56. Kamiya, M. and Nakazato, Y. The expression of p73, p21 and MDM2 proteins in gliomas. J. Neurooncol., 59: 143-149, 2002.
57. Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., and Lozano, G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet., 29: 92-95, 2001.
58. Riemenschneider, M. J., Buschges, R., Wolter, M., Reifenberger, J., Bostrom, J., Kraus, J. A., Schlegel, U., and Reifenberger, G. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res., 59: 6091-6096, 1999.